恒瑞医疗自主研发产品迎来上市十周年纪念

Core Insights - CalliSpheres drug-eluting embolic microspheres developed by Suzhou Heng Rui Medical Devices Co., Ltd. celebrated its 10th anniversary since approval, marking a significant milestone in China's high-end medical device industry [1][2] - The product has received dual certification from the US FDA and EU CE, and has been widely adopted in thousands of hospitals globally, providing treatment for patients with lung and liver cancers [1][2] Industry Context - The global drug-eluting microsphere market was previously dominated by imported products, which were expensive and not fully compatible with the specific needs of Chinese patients, prompting Heng Rui Medical to pursue independent research and development [1] - The introduction of CalliSpheres microspheres represents a shift from "Made in China" to "Intelligent Manufacturing in China," showcasing advancements in domestic medical technology [2] Product Impact - CalliSpheres microspheres have significantly improved access to advanced cancer treatment technologies, with thousands of patients treated across numerous hospitals in China [2] - The product's diverse particle size options and consistent efficacy have facilitated the adoption of TACE technology in grassroots hospitals, allowing more patients to receive quality treatment locally [2] Future Outlook - The continued innovation and technological advancements of CalliSpheres microspheres are expected to elevate the field of interventional medicine in China, reinforcing its position as a representative of Chinese ingenuity on the global stage [2]